Allan S. Jaffe, M.D.

The purpose of this study is to collect samples for hscTnT and hscTnI at baseline in those being started on ICIs who are identified by the clinicians treating these patients and then again subsequently when/if they develop myocarditis and are identified by the CardioOncology service.  The baseline samples will allow for analysis as to whether having an increased hscTn value at baseline is associated with a higher risk of myocarditis.  hscTnT is clinically necessary but hscTnI may not be. Then a proper assessment of the sensitivity, specificity, positive and negative predictive values of this testing will be accomplished.

The objective of this study is to investigate this phenomenon by identifying such patients and analyze this relationship using biomarkers (blood and urine signal proteins) related to volume control such as pro-atrial natriuretic peptide (pro-ANP), N-terminal B-type natriuretic peptide (NT-proBNP), cyclic-GMP (a downstream second messenger for natriuretic peptides) and copeptin (the pre-pro-hormone of antidiuretic hormone).

The purpose of this study is to look at a population of stable End-stage renal disease (ESRD) patients receiving conventional hemodialysis (HD) or peritoneal dialysis, to evaluate the association of elevations in cTnT to: a) Levels of selected biomarkers: N-terminal pro-B-type natriuretic peptide (NT-proBNP), high sensitive C Reactive Protein (hsCRP), Asymmetric Dimethyl Arginine (ADMA); b) Clinical parameters – hypertension, hypotension on HD, left ventricular hypertrophy; c) Biochemical parameters – dyslipidemia, hyperphosphatemia, hyperparathyroidism, erythropoietin resistance.